Immunovant Inc. (NASDAQ:IMVT) is a promising stock to buy under $50. Truist analyst raised price target to $22 on updated financial modeling with a Hold rating. Wolfe Research upgraded to Outperform with $50 target, citing market sentiment shift on Graves’ disease. Guggenheim analyst maintained Buy rating at $41 post-equity offering.

Immunovant Inc. (NASDAQ:IMVT) is a clinical-stage immunology company developing monoclonal antibodies for autoimmune diseases. While IMVT shows investment potential, AI stocks offer greater upside with less risk. For an undervalued AI stock benefiting from tariffs and onshoring trend, see our report on the best short-term AI stock.

Read more at Yahoo Finance: Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling